The study showed that patients with PD-L1 expression in ≥1% tumor cells had a higher risk for PE [OR=1.798 (95%CI 1.137-2.201)], with an incidence of 15.4%, which indicated that PD-L1 expression may be a novel biomarker in prediction of TE in patients with NSCLC (35). The gene discussed is CD274; the disease is neoplasm.